Efficacy and safety of apatinib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial

被引：0
|
作者：
Cai, Z. [1 ]
Zhang, B. [1 ]
Yin, Y. [1 ]
Cao, D. [2 ]
机构：
[1] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Ctr Canc, Dept Abdominal Oncol, Chengdu, Sichuan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1702P
引用
收藏
页码：698 / 698
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
    Demetri, George D.
    Reichardt, Peter
    Kang, Yoon-Koo
    Blay, Jean-Yves
    Rutkowski, Piotr
    Gelderblom, Hans
    Hohenberger, Peter
    Leahy, Michael
    von Mehren, Margaret
    Joensuu, Heikki
    Badalamenti, Giuseppe
    Blackstein, Martin
    Le Cesne, Axel
    Schoffski, Patrick
    Maki, Robert G.
    Bauer, Sebastian
    Binh Bui Nguyen
    Xu, Jianming
    Nishida, Toshirou
    Chung, John
    Kappeler, Christian
    Kuss, Iris
    Laurent, Dirk
    Casali, Paolo G.
    LANCET, 2013, 381 (9863): : 295 - 302
  • [22] Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
    Bao, Q.
    Zhang, Z.
    Wen, J.
    Wan, R.
    Yang, X.
    Chen, X.
    Shen, Y.
    Zhang, W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1712 - S1712
  • [23] Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial
    Xu, Jianming
    Li, Jie
    Bai, Chunmei
    Xu, Nong
    Zhou, Zhiwei
    Li, Zhiping
    Zhou, Caicun
    Jia, Ru
    Lu, Ming
    Cheng, Yuejuan
    Mao, Chenyu
    Wang, Wei
    Cheng, Ke
    Su, Chunxia
    Hua, Ye
    Qi, Chuan
    Li, Jing
    Wang, Wei
    Li, Ke
    Sun, Qiaoling
    Ren, Yongxin
    Su, Weiguo
    CLINICAL CANCER RESEARCH, 2019, 25 (12) : 3486 - 3494
  • [24] Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
    Le Cesne, Axel
    Ray-Coquard, Isabelle
    Bui, Binh Nguyen
    Adenis, Antoine
    Rios, Maria
    Bertucci, Francois
    Duffaud, Florence
    Chevreau, Christine
    Cupissol, Didier
    Cioffi, Angela
    Emile, Jean-Francois
    Chabaud, Sylvie
    Perol, David
    Blay, Jean-Yves
    LANCET ONCOLOGY, 2010, 11 (10): : 942 - 949
  • [25] Efficacy and safety of minocycline in retinitis pigmentosa: a prospective, open-label, single-arm trial
    Chen, Yuxi
    Pan, Yuan
    Xie, Yanyan
    Shi, Yuxun
    Lu, Yao
    Xia, Yiwen
    Su, Wenru
    Chen, Xiaoqing
    Li, Zuoyi
    Wang, Minzhen
    Miao, Siyu
    Yang, Yating
    Jin, Chenjin
    Luo, Guangwei
    Long, Shixian
    Xiao, Hui
    Huang, Chuangxin
    Zhang, Jian
    Liang, Dan
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [26] A single-arm, phase II, multicenter trial of sunitinib maleate (SU) in locally advanced or metastatic
    Leibowitz-Amit, Raya
    Joshua, Anthony Michael
    Ezzat, Shereen
    Bourdeau, Isabelle
    Olney, Harold
    Oosting, Sjoukje
    Ruether, Joseph D.
    Chin, Soo
    Palmieri, Cristina
    Seah, Jo-An
    Assa, Sylvia L.
    Krzyzanowska, Monika
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [27] Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
    Wirth, Lori J.
    Brose, Marcia S.
    Sherman, Eric J.
    Licitra, Lisa
    Schlumberger, Martin
    Sherman, Steven, I
    Bible, Keith C.
    Robinson, Bruce
    Rodien, Patrice
    Godbert, Yann
    De La Fouchardiere, Christelle
    Newbold, Kate
    Nutting, Christopher
    Misir, Soamnauth
    Xie, Ran
    Almonte, Ana
    Ye, Weifei
    Cabanillas, Maria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) : 2359 - +
  • [28] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Kjetil Boye
    Alessandra Longhi
    Tormod Guren
    Susanne Lorenz
    Stine Næss
    Michela Pierini
    Ingeborg Taksdal
    Ingvild Lobmaier
    Marilena Cesari
    Anna Paioli
    Ayca M. Løndalen
    Elisabetta Setola
    Ivar Hompland
    Leonardo A. Meza-Zepeda
    Kirsten Sundby Hall
    Emanuela Palmerini
    Cancer Immunology, Immunotherapy, 2021, 70 : 2617 - 2624
  • [29] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Boye, Kjetil
    Longhi, Alessandra
    Guren, Tormod
    Lorenz, Susanne
    Naess, Stine
    Pierini, Michela
    Taksdal, Ingeborg
    Lobmaier, Ingvild
    Cesari, Marilena
    Paioli, Anna
    Londalen, Ayca M.
    Setola, Elisabetta
    Hompland, Ivar
    Meza-Zepeda, Leonardo A.
    Hall, Kirsten Sundby
    Palmerini, Emanuela
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (09) : 2617 - 2624
  • [30] Efficacy and safety of endostatin in combination with chemotherapy in small cell lung cancer: a phase 2 single-arm multicenter open-label trial
    Zhao, Yi
    Zhang, Xu
    Jin, Chenxing
    Yu, Xiaomin
    Zhang, Min
    Cao, Yang
    Li, Ying
    Wang, Aman
    Shan, Xiu
    Zhang, Jia
    Wang, Juhong
    Yin, Liu
    Tan, Xiaoxin
    Liu, Jiwei
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (03) : 3277 - 3285
12345